Search

Your search keyword '"Schachat, Andrew P."' showing total 14 results
Start Over Author "Schachat, Andrew P." Search Limiters Available in Library Collection
14 results on '"Schachat, Andrew P."'

1. A Prospective Randomized Comparative Dosing Trial of Ranibizumab In Bevacizumab-Resistant Diabetic Macular Edema: The REACT Study

Author

Ehlers, Justis P., Wang, Kevin, Singh, Rishi P., Babiuch, Amy S., Schachat, Andrew P., Yuan, Alex, Reese, Jamie L., Stiegel, Laura, and Srivastava, Sunil K.

Subjects
genetic structures, eye diseases, Article
Abstract

PURPOSE: To assess the efficacy of ranibizumab for persistent diabetic macular edema (DME) previously treated with bevacizumab and compare monthly vs treat-and-extend (TAE) dosing. DESIGN: 12-month, open-label, prospective randomized comparative dosing study. PARTICIPANTS: 27 participants with persistent foveal-involving DME recently treated with bevacizumab. METHODS: All subjects were to receive three initial monthly 0.3 mg ranibizumab injections before randomization to monthly (n=15) or TAE (n=12) injection protocols over 12 months. Treatment interval was extended by two weeks up to a maximum interval of 12 weeks in the TAE group if central subfield thickness (CST) was ≤ 300 μm or complete absence of intraretinal or subretinal fluid on the macular cube was observed. Follow-up interval was decreased by 2 weeks if CST increased above 300 μm with associated intraretinal and/or subretinal fluid. MAIN OUTCOME MEASURES: Change in Early Treatment of Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA), CST, adverse events. RESULTS: Prior to study enrollment, subjects received an average of 8.6 bevacizumab injections. At month 12, mean ETDRS BCVA improved by + 5.3 letters (p

Published
2018

2. Oral eplerenone for the management of chronic central serous chorioretinopathy

Author

Singh, Rishi P, Sears, Jonathan E, Bedi, Rumneek, Schachat, Andrew P, Ehlers, Justis P, and Kaiser, Peter K

Subjects
genetic structures, lcsh:Ophthalmology, Clinical Research, lcsh:RE1-994, subretinal fluid, central serous retinopathy, central serous chorioretinopathy, eplerenone, eye diseases
Abstract

AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR). METHODS: A retrospective consecutive case series was conducted for patients receiving oral eplerenone for chronic CSCR. At baseline and each follow-up visit, spectral domain optical coherence tomography (SD-OCT) imaging was performed, including manual measurements of the height and diameter size of subretinal fluid. The primary outcome measure was the reduction in subretinal fluid following initiation of therapy. RESULTS: A total of 17 eyes of 13 patients treated with 25 and 50 mg of oral eplerenone per day were identified. Subretinal fluid (SRF) decreased over time following eplerenone therapy (P= 0.007 and P = 0.002, diameter and height respectively). Maximum SRF height decreased from a mean of 131.5 μm at baseline to 15.3 μm at day 181+. SRF diameter decreased from an average of 2174.4 μm at baseline to 46.9 μm at day 181+. LogMAR visual acuity improved from 0.42 (Snellen equivalent: 20/53) at baseline to 0.29 (Snellen equivalent: 20/39) at day 181+ (P = 0.024). Central subfield thickness (CST) decreased from 339.5 μm at baseline to 270.3 μm at day 181+ (P = 0.029). CONCLUSION: Eplerenone therapy resulted in significant anatomic and visual improvements in eyes with chronic CSCR.

Published
2015

4. Diabetic Macular Edema Treated With Intravitreal Aflibercept Injection After Treatment With Other Anti-VEGF Agents (SWAP-TWO Study)—12-Month Analysis

Author

Golshani, Cyrus, Conti, Thais F., Conti, Felipe F., Silva, Fabiana Q., Rachitskaya, Aleksandra, Yuan, Alex, Schachat, Andrew, Kaiser, Peter K., Singh, Rishi P., and Babiuch, Amy

Abstract

Purpose: This article reports 12-month outcomes of patients with diabetic macular edema previously treated with other antivascular endothelial growth factor agents and transitioned to fixed dosing of intravitreal aflibercept (IAI).Methods: This prospective, single-arm study enrolled patients to receive IAI 2 mg (0.05 mL) every 4 weeks until optical coherence tomography demonstrated no fluid. Patients then received fixed dosing of IAI 2 mg once every 8 weeks through 12 months. Primary outcome was mean absolute change from baseline central subfield thickness (CST) at 12 months measured by optical coherence tomography.Results: Twenty eyes were enrolled. At baseline, best-corrected visual acuity was 70.0 letters, mean CST was 419.7 µm ± 92.0, superficial capillary perfusion density (CPD) was 46.0 ± 4.2%, and deep CPD was 50.8 ± 4.3%. At 12 months, the mean CST improved to 287.2 µm ± 80.2 (P< .001), superficial CPD decreased to 43.6 ± 4.8% (P= .04), and deep CPD decreased to 47.6 ± 4.8% (P= .05).Conclusions: Patients who switched to fixed dosing of IAI demonstrated significant anatomic improvements in CST at 12 months. CPD values decreased significantly both in superficial and deep layers without significant changes in vision.

Published
2020
Full Text
View/download PDF

5. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis

Author

Singh,Rishi P, Srivastava,Sunil K, Ehlers,Justis P, Silva,Fabiana Q, Bedi,Rumneek, Schachat,Andrew P, Kaiser,Peter K, Singh,Rishi P, Srivastava,Sunil K, Ehlers,Justis P, Silva,Fabiana Q, Bedi,Rumneek, Schachat,Andrew P, and Kaiser,Peter K

Abstract

Rishi P Singh, Sunil K Srivastava, Justis P Ehlers, Fabiana Q Silva, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline.Purpose: Switching therapies in neovascular age-related macular degeneration (AMD) may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI) in subjects previously treated with ranibizumab and/or bevacizumab.Methods: Subjects (n=26) were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST) measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA) early treatment in diabetic retinopathy study (ETDRS) letter score were obtained. Additionally, the percentage of subjects who gained or lost ≥15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated.Results: There was a mean decrease in CST of -50.3  µm (P<0.001) and a mean increase in ETDRS BCVA of +9.2 letters (P<0.001). Twenty-seven percent of subjects experienced a  ≥15-letter improvement in visual acuity, and no subject lost ≥3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12.Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD. Keywords: aflibercept, age-related macular degeneration, bevacizumab, ranibizumab, vascular endothelial growth fa

Published
2015

6. Radiotherapy shows no advantage in choroidal melanoma

Author

GUTTMAN, CHERYL and Schachat, Andrew P.

Subjects
Health
Abstract

BALTIMORE--Five-year follow-up results from the Collaborative Ocular Melanoma Study (COMS) indicate that pre-enucleation radiotherapy (PERT) offers no survival benefit for patients with choroidal ocular melanoma. With 801 of 1,003 entered [...]

Published
1998

7. Photodynamic therapy trials are continuing for AMD

Author

GUTTMAN, CHERYL, Schachat, Andrew P., and Slakter, Jason

Subjects
Health
Abstract

Multicenter studies to evaluate CNV control, whether vision can be stabilized or improved BALTIMORE, MD--Two large, international, randomized, placebo-controlled trials are under way to evaluate the efficacy and safety of [...]

Published
1998

8. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis

Author

Singh, Rishi P., Srivastava, Sunil K., Ehlers, Justis P., Silva, Fabiana Q., Bedi, Rumneek, Schachat, Andrew P., and Kaiser, Peter K.

Subjects
BIOPHARMACEUTICAL research, RETINAL degeneration treatment, INJECTIONS, DRUG administration, RANIBIZUMAB, BEVACIZUMAB, THERAPEUTICS
Abstract

Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline. Purpose: Switching therapies in neovascular age-related macular degeneration (AMD) may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI) in subjects previously treated with ranibizumab and/or bevacizumab. Methods: Subjects (n=26) were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST) measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA) early treatment in diabetic retinopathy study (ETDRS) letter score were obtained. Additionally, the percentage of subjects who gained or lost $15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated. Results: There was a mean decrease in CST of -50.3 µm (P,0.001) and a mean increase in ETDRS BCVA of +9.2 letters (P,0.001). Twenty-seven percent of subjects experienced a $15-letter improvement in visual acuity, and no subject lost $3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12. Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

9. The Economics of Anti-VEGF Treatment.

Author

WEBER, ADAM and SCHACHAT, ANDREW P.

Subjects
DIABETIC retinopathy treatment, VISUAL acuity, VASCULAR endothelial growth factor antagonists, DRUGS & economics, LASERS in ophthalmology, OPHTHALMIC drugs, PATIENT satisfaction, ECONOMICS
Abstract

The article discusses a meta-analysis which investigates the reliability of visual acuity measurements in assessing the true effectiveness of treatments for diabetic retinopathy such as anti-vascular endothelial growth factors. Topics discussed include the patient satisfaction score as the most important measuring stick, laser as a cost-effective treatment of proliferative diabetic retinopathy and the existence of a need for continued cost-effective research particularly in ophthalmology.

Published
2014

10. Outpatient radiotherapy shows promise in AMD feasibility study.

Author

Schachat, Andrew P.

Subjects
*RADIOTHERAPY, *OPHTHALMIC drugs, *RETINAL degeneration treatment, *CATARACT, *VITRECTOMY
Abstract

The article presents the results of a feasibility study which examines the effectiveness of intraocular epiretinal radiotherapy system in treating age-related macular degeneration (AMD). Findings of the study indicate that epiretinal radiotherapy treatment combined with bevacizumab provides better outcomes and minimal effects of cataract, intraretinal bleeding, and subretinal fibrosis. Epiretinal radiotherapy system was employed during partial vitrectomy under local anesthesia.

Published
2007

11. Editorial Comment

Author

Miller, Neil R., Schachat, Andrew P., and Boldt, Culver

Published
1991

13. Ophthalmic drugs may affect developing eye of fetus.

Author

Barrere, Michele, Murphree, A. Linn, Schachat, Andrew P., Miller, Marilyn, and Sunness, Janet

Subjects
OPHTHALMIC drugs, PREGNANT women, HEALTH
Abstract

Discusses how ophthalmic drugs could affect developing eye of fetus. Ophthalmic drugs to be avoided by pregnant women; Medications which are safe to use during pregnancy; Why fluorescein angiography (FA) should be avoided by pregnant patients.

Published
1999

14. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.

Author

Yuan A, Ahmad BU, Xu D, Singh RP, Kaiser PK, Martin DF, Sears JE, Schachat AP, and Ehlers JP

Abstract

Aim: To compare the efficacy of ranibizumab and bevacizumab for macular edema due to retinal vein occlusion (RVO)., Methods: A retrospective study was conducted at a single academic institution. Eighty-one patients naïve to anti-VEGF therapy with RVO and macular edema were identified. Twenty-six eyes were treated with ranibizumab, 33 eyes with bevacizumab, and 22 eyes with bevacizumab then switched to ranibizumab (crossover). The main outcome was change in visual acuity at 3 months, 6 months, and final visit., Results: The mean visual acuity improved from 20/80 to 20/40 in the ranibizumab (R) group and from 20/125 to 20/60 in the bevacizumab (B) group (P=0.66). The mean change in central subfield thickness (CST) was -186 and -212µm, respectively (P=0.69). Mean time between injections was 94±21.1d in the R group and 103.8±10.5d in the B group (P=0.78). In the crossover group, mean initial visual acuity was 20/125, reached 20/60 at crossover, and remained 20/60 at conclusion (P=0.91)., Conclusion: Both ranibizumab and bevacizumab are effective for the treatment of RVO and appear to have similar visual and anatomic outcomes. Changing treatments from bevacizumab to ranibizumab did not result in further gains in visual acuity.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results